Multiple Sclerosis Drugs and Therapeutic Pipeline Review H1 2017 Research Available at RnR Market Research

Tuesday, July 4, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

PUNE, India, July 4, 2017 /PRNewswire/ --

Multiple Sclerosis Pipeline Review H1 2017 therapeutic market research

report of 812 pages with latest updates, data and information which provides an overview of the therapeutics development for Multiple Sclerosis by major pharmaceutical companies.

The Multiple Sclerosis Pipeline Review H1 2017 provides

comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action, route of administration and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Complete report is available at .

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies discussed in this report include  2-BBB Medicines BV, 4D Pharma PLC, AB Science SA, AbbVie Inc, Abion Inc, Ablynx NV, Abzena Plc, Acorda Therapeutics Inc, Actelion Ltd, Adamas Pharmaceuticals Inc, Addex Therapeutics Ltd, Adhaere Pharmaceuticals Inc, Aegis Therapeutics LLC, Affectis Pharmaceuticals AG, AiCuris GmbH & Co KG, Alkermes Plc, Allergan Plc, Alpha Cancer Technologies Inc, Alvotech Iceland, Amarna Therapeutics BV, Anavex Life Sciences Corp, Antisense Therapeutics Ltd, Aphios Corp, Apitope International NV, ARA Healthcare Pvt Ltd, Argos Therapeutics Inc, Arrien Pharmaceuticals LLC, Artielle ImmunoTherapeutics Inc, Arven Ilac, Asterias Biotherapeutics Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, Athersys Inc, Atlantic Bio Sci LLC, Axxam SpA, Bio-Cancer Treatment International Ltd, BioApex sro, Biocad, Biocon Ltd, Biogen Inc, BioHealthonomics Inc, Biomar Microbial Technologies, Bionovis SA, Bionure Farma SL, Biovista Inc, Bolder Biotechnology Inc, BrainStorm Cell Therapeutics Inc, Bristol-Myers Squibb Company, CASI Pharmaceuticals Inc, Catalyst Pharmaceuticals Inc, Celgene Corp, Cell Cure Neurosciences Ltd, Cell2B Advanced Therapeutics SA, Cinnagen Co, Cognosci Inc, Coherus BioSciences Inc, Commence Bio Inc, Compugen Ltd, Connexios Life Sciences Pvt Ltd, Critical Outcome Technologies Inc, CuraVac Inc, Cyxone AB, DanDrit Biotech A/S, Denceptor Therapeutics Ltd, Dimerix Bioscience Pty Ltd, Eisai Co Ltd, Eli Lilly and Company, Evgen Pharma Plc, Evotec AG, F. Hoffmann-La Roche Ltd, Flex Pharma Inc, Forward Pharma A/S, FPRT Bio Inc, Gemac SA, Genervon Biopharmaceuticals LLC, GeNeuro SA, Genzyme Corp, GlaxoSmithKline Plc, Glialogix Inc, Hansa Medical AB, Harbor Therapeutics Inc, Humabs BioMed SA, Hutchison China MediTech Ltd, Immune Response BioPharma Inc, Immune Therapeutics Inc, Immungenetics AG, Immunwork Inc, Inception Sciences Inc, Innate Immunotherapeutics Ltd, Inovio Pharmaceuticals Inc, Io Therapeutics Inc, Jyant Technologies Inc, Kadimastem Ltd, Kadmon Corp LLC, KAHR medical Ltd, KaloBios Pharmaceuticals Inc, Kancera AB, Karo Pharma AB, Karyopharm Therapeutics Inc, Kissei Pharmaceutical Co Ltd, KPI Therapeutics Inc, Kyorin Pharmaceutical Co Ltd, Lead Discovery Center GmbH, LFB SA, Lipocure Ltd, MacroGenics Inc, Mapi Pharma Ltd, Marathon Pharmaceuticals LLC, MedAnnex Ltd, MedDay SA, Medestea Research & Production SpA, MedImmune LLC, Merck KGaA, Meta-IQ ApS, Mitochon Pharmaceuticals Inc, Mitotech SA, Mitsubishi Tanabe Pharma Corp, Mochida Pharmaceutical Co Ltd, MorphoSys AG, Mount Tam Biotechnologies Inc, Neuralstem Inc, Neuren Pharmaceuticals Ltd, Neurofx Inc, Neuronax SAS, New World Laboratories Inc, Novartis AG, Nuevolution AB, Numab Innovation AG, Ogeda SA, Omeros Corp, OncoImmune Inc, Opexa Therapeutics Inc, Oryzon Genomics SA, OSE Immunotherapeutics, Pangen Biotech Inc., Parvus Therapeutics Inc, Pfenex Inc, Pfizer Inc, Pharmaxis Ltd, ProNoxis AB, Prothena Corp Plc, Quimatryx SL, ReceptoPharm Inc, RedHill Biopharma Ltd, RegeneRx Biopharmaceuticals Inc, Regenesance BV, Renovo Neural Inc, Resverlogix Corp, ReveraGen BioPharma Inc, Rigel Pharmaceuticals Inc, Rock Creek Pharmaceuticals Inc, Rodos BioTarget GmbH, SanBio Inc, Santhera Pharmaceuticals Holding AG, Sareum Holdings Plc, Senju Pharmaceutical Co Ltd, Sorrento Therapeutics Inc, Spherium Biomed SL, Symic Biomedical Inc, Synthon Holdings BV, Teikoku Pharma USA Inc, Teva Pharmaceutical Industries Ltd, TikoMed AB, Tiziana Life Sciences Plc, Toleranzia AB, Topas Therapeutics GmbH, TxCell SA, Vaccinex Inc, Vakzine Projekt Management GmbH, Vicore Pharma AB, viDA Therapeutics Inc, Virogenomics BioDevelopment Inc, VivaCell Biotechnology Espana SL, Xenetic Biosciences Inc, XL-protein GmbH, Yungjin Pharm Co Ltd, Zydus Cadila Healthcare Ltd.

Order a Purchase copy of this report at .

Similar report title Multiple Sclerosis - Market Insights, Epidemiology and Market Forecast-2023 provides an overview of the disease and global market trends of the Multiple Sclerosis for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Multiple Sclerosis forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Multiple Sclerosis till 2023.

Explore more reports of Pharmaceuticals Market Research at .

About Us: is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.

Contact: Ritesh Tiwari 2nd Floor, Metropole, Bund Garden Road, Pune - 411001, India. Tel: + 1-888-391-5441 E-mail:

SOURCE RnRMarketResearch

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store